• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GSS

GENETIC SIGNATURES LIMITED - Charts / Financials

72.8% ! 14.0¢
Market Cap $18.39M  !
Healthcare Diagnostics & Research
Add to My Watchlist

Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx)... Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others. More

refresh Created with Sketch. REFRESH
Last update - 14.59pm 15/04/2026 (20 minute delay) ?
Day
Open 9.2¢   Day High 14.0¢   Day Low 9.2¢
Daily Volume 2024664
Bids   Sellers
Number Price Volume   Number Price Volume
0 17.0¢ 12500   0 13.5¢ 10000

Directors & Senior Management

Ms. Anne Nicole Lockwood Interim MD & Director
Ms. Caroline C. Waldron Chairman of the Board
Mr. Christopher M. Abbott Founder & Chairman Emeritus
Dr. Jenny Lee Harry Independent Non-Executive Director
Ms. Maria Halasz Chief Executive Officer
Mr. Michael Anton Aicher Executive Director of US Operations & Executive Director
Dr. Neil Gunn Non-Executive Director
Ms. Rebecca Abbatantuono Chief People Officer
Dr. Susanne K. Pedersen Chief Technology Officer

Data source: ADVFN

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
14.0¢ 		Change
0.059(72.8%) 		Mkt cap ! $18.39M
Open High Low Volume
9.2¢ 14.0¢ 9.2¢ 2.024M

Buyers (Bids)

Vol. Price($)
12500 17.0¢
 

Sellers (Offers)

Price($) Vol.
13.5¢ 10000
Last trade - 14.59pm 15/04/2026 (20 minute delay) ?

Top Stories

Prairie's reality: Execution has become new alpha in North American lithium race

As any good HotCopper reader worth their salt knows ⁠@ and I know you’re one of them, dear reader ⁠@ the lithium narrative has long hinged on two variables: Resource size and grade. Our HotCopper forums are filled with investors scouring feasibility studies for the...
Federal gov't pours cold water on QLD's Taroom fast track call being called a 'generational opportunity' The Queensland government says the Taroom Trough should receive special support due to its potential to provide fuel security for Australia.
Ore Resources reports early Phase 4 drilling results pointing to expanding gold system at Forrest prospect Ore Resources (ASX:OR3) is continuing to build momentum at its Coolgardie project in Western Australia, where it’s been rolling out a large-scale Phase 4 drilling program. The company has just released its drilling results from its latest program, and it’s all look...
HotCopper Highlights, Week 15: Santos, Karoon, Viva all riding the Iran-fuelled Energy rollercoaster Hello, hello, and welcome to HotCopper Highlights for Week 15, CY26, I’m Isaac McIntyre. In this segment, we wrap up the stocks and company announcements you were watching this week on Australia’s #1 finance website. Let’s get straight into it, star...
US growth, injectable iron pipeline: How AFT Pharma is driving toward $300 million by FY27 AFT Pharmaceuticals (ASX:AFP) is in a red-hot position as we head straight into FY26’s fourth quarter in Australia, and founder and managing director Hartley Atkinson believes it’s only going to get better as the growing Oz-based multinational pharmaceutical compan...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.